Comparative Effectiveness of Carvedilol versus Metoprolol Succinate in Reducing Implantable Cardioverter Defibrillator Therapy Burden Among Heart Failure Patients (CARVTOP-ICD)
PI(s): Mehmet Aktas (University of Rochester Medical Center); Ilan Goldenberg (University of Rochester Medical Center)
Purpose: The study is comparing two heart medications, carvedilol (Coreg) and metoprolol succinate (Toprol), in people with heart failure who have an implantable defibrillator (ICD). The study aims to see which medication is better at preventing abnormal heart rhythms, reducing ICD shocks, lowering the risk of heart-related hospital visits or death, and improving patients’ quality of life.
Study Design: Interventional
PCORnet® Partners:
- New York Presbyterian Hospital/Columbia
- University of Missouri
- University of Utah School of Medicine
PaTH Partners:
- Johns Hopkins University
Sponsor: PCORI®
The CARVTOP-ICD study is a PCORnet® Study conducted using PCORnet®, the National Patient Centered Clinical Research Network, an initiative funded by the Patient-Centered Outcomes Research Institute (PCORI). More information about PCORnet® can be found here.
The trial was funded by PCORI through PCORI Award PLACER-2023C3-33489.
The statements presented on this website are solely the responsibility of the author(s) and do not necessarily represent the views of other organizations participating in, collaborating with, or funding PCORnet or of PCORI.
Coordinating Center: University of Rochester
How to participate: Interested individuals should contact their cardiologist and a participating study site to see if they meet the eligibility criteria. The study team will explain all procedures, medications, and answer any questions before enrollment.
